Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

FDA approves Zevra’s Miplyffa as first drug for Niemann-Pick disease type C

The rare lysosomal storage disorder affects approximately 900 people in the US

- PMLiVE

The partnership triangle

To truly make a sustainable difference, we need the engagement of all stakeholders

- PMLiVE

AI in market access: silver bullet or spanner in the works?

By Emily Morton-West

Amiculum

- PMLiVE

Driving behaviour change for positive patient outcomes in pharma

Discover how pharma can help to achieve better patient health outcomes by informing patient behaviour through insights, strategy and collaboration.

Graphite Digital

- PMLiVE

How Design Systems enable streamlined regulatory approval in digital pharma

The strict compliance guidelines that exist within pharma can mean that digital content and platforms can take a long time to be approved and involve lots of back and forth...

Graphite Digital

- PMLiVE

What is willingness to pay? – Comparing price testing methodologies

Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

Petauri Evidence

- PMLiVE

Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults

The rare liver disease affects approximately nine women for every one man

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients

If approved, Dupixent would be the first drug in the EU indicated for this patient population

- PMLiVE

From lab to life: harnessing real-world evidence for informed clinical insights and improved patient outcomes

By Stephen Deacon

- PMLiVE

Embracing risk: it’s time for big thinking in neurodegeneration

Drug discovery is an inherently risky endeavour, but society relies upon new drug discoveries and innovations

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links